INBX 8-K
Inhibrx Biosciences, Inc. (INBX)
8-K
2024-11-14
For: 2024-11-14
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2024
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858 ) 795-4220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition
On November 14, 2024, Inhibrx Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2024 | ||||||||
| INHIBRX BIOSCIENCES, INC. | ||||||||
| By: | /s/ Kelly Deck | |||||||
| Name: | Kelly Deck | |||||||
| Title: | Chief Financial Officer | |||||||
Exhibit 99.1
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
San Diego, CA, November 14, 2024 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx Biosciences” or the “Company”) today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. and the Former Parent’s concurrent spin-off of the Inhibrx Biosciences business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company’s financial statements are the historical financial statements of the Former Parent.
Financial Results
•Cash and Cash Equivalents. As of September 30, 2024, Inhibrx Biosciences had cash and cash equivalents of $196.3 million, compared to $226.9 million as of June 30, 2024. Cash outflows in the period primarily consisted of payments for its ongoing operations, including payments made to its third party contract development and manufacturing organizations (“CDMOs”) and contract research organizations (“CROs”) in support of the Company’s ongoing clinical trials.
•R&D Expense. Research and development expenses were $38.9 million during the third quarter of 2024, compared to $38.1 million during the third quarter of 2023. The increase in research and development expenses was primarily due to:
◦an increase in clinical trial expenses due to the expansion of the Company’s ongoing registration-enabling Phase 2 trial for ozekibart (INBRX-109) for the treatment of unresectable or metastatic conventional chondrosarcoma. Clinical trial expenses also increased as a result of the expansion of the INBRX-106 Phase 1/2 trial and the initiation of the Phase 2/3 trial in head and neck squamous cell carcinoma, including expenses for in-house clinical trial support;
◦offset in part by a decrease in stock option expense as a result of fewer stock options outstanding in the current period under the Company’s new 2024 Omnibus Incentive Plan (the “2024 Plan”) following the termination of its prior plan in connection with the spin-off.
•G&A Expense. General and administrative expenses were $7.9 million during each of the third quarters of 2024 and 2023. The composition of general and administrative expenses fluctuated due to:
◦a decrease in stock option expense as a result of fewer stock options outstanding in the current period under the 2024 Plan following the termination of its prior plan in connection with the spin-off;
◦offset by an increase in professional service expenses related to legal and accounting services to support general corporate and intellectual property matters as well as legal proceedings.
•Other Income (Expense). Other income was $2.9 million during the third quarter of 2024, compared to other expense of $6.0 million during the third quarter of 2023.
Following the Company’s spin-off transaction in the second quarter of 2024, the Company no longer has any outstanding third-party debt, and therefore did not incur any interest expense during the period. Other income consists of interest earned on the Company’s sweep and money market account balances.
•Net Loss. Net loss was $43.9 million during the third quarter of 2024, or $2.84 per share, basic and diluted, compared to a net loss of $51.8 million during the third quarter of 2023, or $4.39 per share, basic and diluted.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences’ current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.
Forward Looking Statements
Inhibrx Biosciences cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx Biosciences’ current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding expected data readouts and the timing thereof and the Company’s ability to develop therapeutic candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx Biosciences’ business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; the Company’s ability to utilize the Company’s technology platform to generate and advance additional therapeutic candidates; the implementation of the Company’s business model and strategic plans for the Company’s business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company’s therapeutic candidates; the ability to raise funds needed to satisfy the Company’s capital requirements, which may depend on financial, economic and market conditions and other factors, over which the Company may have no or limited control; the Company’s financial performance; developments relating to the Company’s competitors and the Company’s industry; and other risks described from time to time in the “Risk Factors” section of its filings with the U.S. Securities and Exchange Commission, including those described in its Registration Statement on Form 10, as amended (File No. 001-42031), its Registration Statement on Form S-1, as amended and supplemented from time to time (File No. 333-280127), and its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K
as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx Biosciences undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact:
Kelly D. Deck
Chief Financial Officer
858-795-4260
Inhibrx Biosciences, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
| THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
| License fee revenue | $ | — | $ | 119 | $ | 100 | $ | 166 | |||||||||||||||
| Total revenue | — | 119 | 100 | 166 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 38,893 | 38,057 | 170,376 | 109,549 | |||||||||||||||||||
| General and administrative | 7,904 | 7,889 | 111,244 | 21,549 | |||||||||||||||||||
| Total operating expenses | 46,797 | 45,946 | 281,620 | 131,098 | |||||||||||||||||||
| Loss from operations | (46,797) | (45,827) | (281,520) | (130,932) | |||||||||||||||||||
| Total other income (expense) | 2,933 | (5,960) | 2,016,959 | (16,818) | |||||||||||||||||||
| Provision for income taxes | — | 2 | 2 | 7 | |||||||||||||||||||
| Net income (loss) | $ | (43,864) | $ | (51,789) | $ | 1,735,437 | $ | (147,757) | |||||||||||||||
| Earnings (loss) per share | |||||||||||||||||||||||
| Basic | $ | (2.84) | $ | (4.39) | $ | 119.04 | $ | (13.19) | |||||||||||||||
| Diluted | $ | (2.84) | $ | (4.39) | $ | 117.09 | $ | (13.19) | |||||||||||||||
| Shares used in computing earnings (loss) per share | |||||||||||||||||||||||
| Basic | 15,468 | 11,788 | 14,578 | 11,201 | |||||||||||||||||||
| Diluted | 15,468 | 11,788 | 14,821 | 11,201 | |||||||||||||||||||
Inhibrx Biosciences, Inc.
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
| SEPTEMBER 30, | DECEMBER 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Cash and cash equivalents | $ | 196,332 | $ | 277,924 | |||||||
| Other current assets | 11,114 | 17,434 | |||||||||
| Non-current assets | 15,116 | 12,535 | |||||||||
| Total assets | $ | 222,562 | $ | 307,893 | |||||||
| Debt, current and non-current | $ | — | $ | 206,968 | |||||||
| Other current liabilities | 44,095 | 56,312 | |||||||||
| Other non-current liabilities | — | 1,110 | |||||||||
| Total liabilities | 44,095 | 264,390 | |||||||||
| Stockholders’ equity | 178,467 | 43,503 | |||||||||
| Total liabilities and stockholders’ equity | $ | 222,562 | $ | 307,893 | |||||||